Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Happy Mohamed

HISTORICAL FACTS: What s going on with caribou biosciences shares today - The Untold Story

Caribou Biosciences, Inc. (NASDAQ:CRBU) shares are trading lower after the company reported additional data from its CB-010 allogeneic CAR-T cell therapy Phase 1 ANTLER trial at the European Hematology Association 2022 Hybrid Congress.

A 100% complete response rate (6 of 6 patients) was observed as best response, with a 40% complete response rate (2 of 5 patients) at 6 months.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.